News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Legal Momentum Grows Against IRA

June 23, 2023
By Lisa Henderson
Article

Complaints filed against CMS target the unconstitutionality of the Act, while the stifling of innovation in biopharma runs a parallel argument for numerous reasons

Image credit: AdobeStock_527614812 [Inflation Reduction Act is shown using the text and the US flag, By Andrii]

Image credit: AdobeStock_527614812 (Inflation Reduction Act is shown using the text and the US flag, By Andrii)

Pharmaceutical Research and Manufacturers of America (PhRMA) along with the National Infusion Center Association (NICA), and the Global Colon Cancer Association (GCCA), filed a complaint in U.S. District Court for the Western District of Texas against the Inflation Reduction Act (IRA) Thursday, June 21.1 According to a statement from PhRMA, the statute violates the Constitution’s separation of power and due process clauses and includes an extreme excise “tax” to force manufacturer compliance with the government mandated price. The statement said, based on violations of the Fifth and Eighth Amendments to the Constitution, the whole Act should be ruled unconstitutional.

This complaint follows the June 6 complaint filed a civil action in the United States District Court for the District of Columbia.2 Merck, known as MSD outside of the United States and Canada, also alleges that the price controls introduced by the IRA, which require the Centers for Medicare and Medicaid Services to begin setting prices on small molecule medicines at nine years and large molecule medicines at 13 years, are unconstitutional.3

Outside of the pure legal aspects, both Merck and the joint plaintiffs in the PhRMA complaint, assert that the IRA will stifle biopharmaceutical innovation.

For example, in a letter to the community, Merck stated: “Patients and the public need biopharmaceutical innovation to address global health challenges like cancer and Alzheimer’s disease, and the IRA is negatively affecting critical research and development. By changing the incentives and returns for some therapies and technologies over others, the IRA is changing the course of R&D, which in time will leave many patients without treatment options.”2

Contained within the PhRMA release, PhRMA President and CEO Stephen J. Ubl stated, in part: "The price setting scheme in the Inflation Reduction Act is bad policy that threatens continued research and development and patients’ access to medicines.”1 Previously, Ubl has described the innovation conundrum in detail.4

Meanwhile, organizations representing patients, are against the IRA for numerous reasons.

In the PhRMA press release, NICA Chief Executive Officer Brian Nyquist noted what could be construed as a “unintended consequences: of the IRA. “NICA supports lower costs for patients, but infusion providers have no control over setting the prices of the medications they administer. NICA’s members have an interest in being adequately reimbursed for the treatments they provide, and they have an interest in continuing to operate their healthcare business. The government price setting provisions in the IRA may inadvertently set reimbursement below acquisition cost, exacerbating existing consolidation trends and reducing our nation’s community-based infusion capacity. This would leave patients with the hospital as their only option—which is by far the most expensive setting.”1

GCCA Executive Director Andrew Spiegel cited the lack of current treatments as a reason to not stifle innovation. He stated in part, “In less than seven years, colorectal cancer is predicted to become the leading cause of cancer deaths for people under 50, and it is already the second leading cause of all cancer deaths, behind only lung cancer. We need more and better treatments, and we need them now. The price setting provisions in the IRA thwart the progress we have made and lead to less hope for patients battling this disease.”1


References

  1. NICA, GCCA, PhRMA Litigation Asserts Price Setting Provisions in the Inflation Reduction Act are Unconstitutional. WASHINGTON, D.C. June 21, 2023.
  2. The Inflation Reduction Act’s Negative Impact on Patient-Focused Innovation, Value and Access. https://www.merck.com/news/the-inflation-reduction-acts-negative-impact-on-patient-focused-innovation-value-and-access. June 6, 2023.
  3. Playter, G. Merck Files Lawsuit Against US Government. Pharmaceutical Technology. https://www.pharmtech.com/view/merck-files-lawsuit-against-us-government. June 8, 2023.
  4. Ubl, S.; Herper, M. The Inflation Reduction Act: Unfinished Business. Presentation at PhRMA Foundation, November 15, 2022. https://phrma.org/resource-center/Topics/Economic-Impact/The-Inflation-Reduction-Act-Unfinished-Business
Recent Videos
Related Content

Stock.adobe.com

GSK and Lifetime Produce Meningitis-Themed Film

Mike Hollan
May 21st 2025
Article

The film tells the story of a family impacted by the disease and shares the importance of checking to make sure that children are vaccinated against all strains.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Andres Acosta, MD, PhD

Predicting GLP-1 Side Effects: Q&A with Andres Acosta, MD, PhD

Mike Hollan
May 20th 2025
Article

The ability to predict side effects such as nausea before starting treatment represents a paradigm shift in precision medicine.


BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

Don Tracy, Associate Editor
May 19th 2025
Article

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.

Related Content

Stock.adobe.com

GSK and Lifetime Produce Meningitis-Themed Film

Mike Hollan
May 21st 2025
Article

The film tells the story of a family impacted by the disease and shares the importance of checking to make sure that children are vaccinated against all strains.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Andres Acosta, MD, PhD

Predicting GLP-1 Side Effects: Q&A with Andres Acosta, MD, PhD

Mike Hollan
May 20th 2025
Article

The ability to predict side effects such as nausea before starting treatment represents a paradigm shift in precision medicine.


BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

Don Tracy, Associate Editor
May 19th 2025
Article

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.